Agency
Geisinger Lewistown Hospital
Geisinger Lewistown Hospital was paid $9.74M by Medicaid between May 2018 and Dec 2024, across 270 billing codes. Its largest line is 99285, emergency room visit (most serious) — 20% of everything it billed.
33Billing provider infoGEISINGER LEWISTOWN HOSPITAL
LEWISTOWN, PA 17044
LEWISTOWN, PA 17044
33aNPI1861545683assigned 01/18/2007
33bProvider typePublic Health or Welfare Agency
28Total paid$9.74M
24GClaims346,817
24DCodes billed270
24AFirst – last monthMay 2018 – Dec 2024
Compared with peers
Next to other Public Health or Welfare Agency providers in Pennsylvania
Rank by total paid#7 of 52
Median peer was paid$1.61M
This provider vs. median6.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official MULL, CINDY controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 79 | $4K | |
| 2019 | 212 | $4K | |
| 2020 | 28,066 | $691K | |
| 2021 | 120,128 | $3.29M | |
| 2022 | 67,963 | $1.91M | |
| 2023 | 72,347 | $1.97M | |
| 2024incomplete | 58,022 | $1.87M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 20% | 15,442 | 14,707 | $1.98M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 14% | 13,453 | 12,948 | $1.36M |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 9.9% | 4,973 | 4,784 | $968K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 8.7% | 11,628 | 11,296 | $849K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | 3.4% | 3,938 | 3,825 | $333K |
| 80053 | Comprehensive metabolic panel | 3.1% | 29,245 | 27,113 | $304K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.4% | 1,383 | 1,348 | $236K |
| G0378 | Hospital observation service, per hour | 2.2% | 322 | 234 | $218K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 2.0% | 7,098 | 6,845 | $191K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.7% | 2,084 | 2,021 | $165K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.7% | 30,623 | 28,340 | $161K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.3% | 2,083 | 1,866 | $129K |
258 more codes
| 87631 | 1.2% | 857 | $121K | |
| 84443 | Thyroid stimulating hormone (TSH) | 1.2% | 5,392 | $113K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 1,509 | $91K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 9,662 | $85K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 6,189 | $81K |
| 0100U | <1% | 204 | $78K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 4,403 | $77K |
| 80061 | Lipid panel | <1% | 5,739 | $73K |
| 84484 | <1% | 8,111 | $72K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 2,071 | $62K |
| 87481 | <1% | 853 | $62K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 986 | $60K |
| 84702 | <1% | 3,574 | $57K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 286 | $57K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 3,409 | $55K |
| 71045 | Radiologic examination, chest; single view | <1% | 5,752 | $50K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,926 | $48K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 5,757 | $42K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 440 | $42K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 1,218 | $40K |
| 0002A | <1% | 1,095 | $40K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,653 | $40K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 5,402 | $39K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 136 | $37K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 929 | $37K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 443 | $35K |
| 0001A | <1% | 1,122 | $35K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 178 | $33K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 145 | $33K |
| 62323 | <1% | 61 | $33K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 704 | $31K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 334 | $30K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 872 | $29K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 4,802 | $29K |
| 83690 | <1% | 5,824 | $27K | |
| 87150 | <1% | 305 | $26K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 290 | $26K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 199 | $26K |
| 300 | Patient transfer system <300 | <1% | 182 | $24K |
| 82607 | <1% | 2,050 | $24K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 84 | $24K |
| 83605 | <1% | 3,351 | $23K | |
| 85027 | <1% | 4,201 | $22K | |
| 80050 | General health panel | <1% | 493 | $21K |
| 76830 | Ultrasound, transvaginal | <1% | 374 | $21K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 287 | $19K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 688 | $19K |
| 71250 | <1% | 276 | $18K | |
| 83880 | <1% | 682 | $18K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 9,834 | $18K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,517 | $17K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 400 | $16K |
| 76642 | <1% | 331 | $16K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 827 | $16K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 512 | $16K |
| 81001 | <1% | 5,630 | $15K | |
| 82728 | <1% | 1,404 | $15K | |
| 83735 | <1% | 2,591 | $14K | |
| 86803 | <1% | 765 | $14K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 186 | $14K |
| 87430 | <1% | 2,038 | $13K | |
| 76770 | <1% | 225 | $12K | |
| Q9957 | Injection, perflutren lipid microspheres, per ml | <1% | 163 | $12K |
| 82805 | <1% | 406 | $11K | |
| X0621 | <1% | 53 | $11K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 1,067 | $11K |
| 83540 | <1% | 1,298 | $10K | |
| T1015 | A visit at a community health center or clinic (one all-in rate) | <1% | 301 | $9K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 287 | $9K |
| 0004A | <1% | 210 | $9K | |
| 85379 | <1% | 992 | $9K | |
| 84439 | <1% | 1,145 | $9K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 331 | $8K |
| 88342 | <1% | 190 | $8K | |
| 87040 | <1% | 516 | $8K | |
| 87522 | Neg quan hep c or qual rna | <1% | 199 | $8K |
| 93971 | <1% | 113 | $7K | |
| 82570 | <1% | 1,058 | $7K | |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 946 | $7K |
| 73610 | <1% | 359 | $7K | |
| 74183 | <1% | 13 | $7K | |
| 81003 | <1% | 2,374 | $7K | |
| 73564 | <1% | 278 | $6K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 73 | $6K |
| 85610 | <1% | 2,318 | $6K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 3,746 | $6K |
| 73630 | <1% | 439 | $6K | |
| 82043 | <1% | 802 | $6K | |
| 87186 | <1% | 765 | $5K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 27 | $5K |
| 82248 | <1% | 926 | $5K | |
| 83550 | <1% | 1,238 | $5K | |
| 86618 | <1% | 220 | $5K | |
| 81025 | <1% | 1,314 | $5K | |
| 74018 | <1% | 339 | $5K | |
| 80076 | <1% | 668 | $5K | |
| 82746 | <1% | 458 | $5K | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 584 | $4K |
| 83655 | <1% | 394 | $4K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 120 | $4K |
| 72100 | <1% | 175 | $4K | |
| 84145 | <1% | 248 | $4K | |
| 84153 | <1% | 171 | $4K | |
| 86850 | <1% | 546 | $4K | |
| 73030 | <1% | 236 | $4K | |
| 84146 | <1% | 152 | $4K | |
| 94060 | <1% | 410 | $4K | |
| 86780 | <1% | 253 | $4K | |
| 0012A | <1% | 129 | $4K | |
| 83615 | <1% | 702 | $4K | |
| 87077 | <1% | 530 | $3K | |
| 0064A | <1% | 80 | $3K | |
| 72141 | <1% | 13 | $3K | |
| 76536 | <1% | 56 | $3K | |
| 77065 | Tomosynthesis, mammo | <1% | 53 | $3K |
| 86140 | <1% | 1,138 | $3K | |
| Q3014 | Telehealth originating site facility fee | <1% | 230 | $3K |
| 86900 | <1% | 686 | $3K | |
| 83970 | <1% | 81 | $3K | |
| 86901 | <1% | 683 | $3K | |
| 87340 | <1% | 215 | $3K | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 181 | $3K |
| 73130 | <1% | 221 | $3K | |
| 96376 | <1% | 112 | $3K | |
| 84100 | <1% | 622 | $3K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 6,707 | $3K |
| 0072A | <1% | 63 | $3K | |
| 93226 | <1% | 73 | $3K | |
| 86003 | <1% | 26 | $3K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 80 | $2K |
| 87088 | <1% | 310 | $2K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 191 | $2K |
| 82962 | <1% | 1,528 | $2K | |
| 80081 | <1% | 25 | $2K | |
| 73502 | <1% | 107 | $2K | |
| 88341 | <1% | 29 | $2K | |
| 72110 | <1% | 79 | $2K | |
| 73110 | <1% | 153 | $2K | |
| 0071A | <1% | 47 | $2K | |
| 90715 | <1% | 418 | $2K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 173 | $2K |
| 94729 | <1% | 65 | $2K | |
| 0011A | <1% | 108 | $2K | |
| 82950 | <1% | 250 | $2K | |
| 86038 | <1% | 115 | $2K | |
| 93017 | <1% | 45 | $2K | |
| 70486 | <1% | 24 | $2K | |
| 82375 | <1% | 408 | $2K | |
| 84481 | <1% | 74 | $2K | |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 55 | $2K |
| 12001 | <1% | 65 | $2K | |
| 86592 | <1% | 388 | $2K | |
| 82550 | <1% | 263 | $2K | |
| 82565 | <1% | 267 | $2K | |
| 86762 | <1% | 78 | $2K | |
| 83525 | <1% | 139 | $2K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,468 | $1K |
| 85652 | <1% | 501 | $1K | |
| 94726 | <1% | 52 | $1K | |
| 82150 | <1% | 320 | $1K | |
| 85046 | <1% | 251 | $1K | |
| 77066 | Tomosynthesis, mammo | <1% | 13 | $1K |
| 82977 | <1% | 201 | $1K | |
| 87070 | <1% | 193 | $1K | |
| 86431 | <1% | 157 | $1K | |
| 82784 | <1% | 54 | $1K | |
| 84156 | <1% | 272 | $1K | |
| 80164 | <1% | 70 | $1K | |
| 73590 | <1% | 55 | $1K | |
| 0003A | <1% | 23 | $950.20 | |
| 93320 | <1% | 24 | $934.46 | |
| 85730 | <1% | 157 | $901.47 | |
| 84550 | <1% | 163 | $899.47 | |
| 83050 | <1% | 406 | $861.60 | |
| 93225 | <1% | 51 | $844.44 | |
| 86317 | <1% | 41 | $828.34 | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 38 | $779.42 |
| 73080 | <1% | 63 | $778.77 | |
| 11721 | <1% | 59 | $756.00 | |
| 94664 | <1% | 96 | $746.64 | |
| 85018 | <1% | 241 | $739.22 | |
| 80179 | <1% | 13 | $733.26 | |
| 84403 | <1% | 25 | $731.16 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 646 | $668.84 |
| 82947 | <1% | 169 | $664.30 | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 31 | $645.45 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 947 | $645.37 |
| 80074 | <1% | 13 | $627.74 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 5,409 | $605.31 |
| 74022 | <1% | 32 | $602.21 | |
| 20552 | <1% | 28 | $599.96 | |
| 85007 | <1% | 146 | $583.39 | |
| 87511 | <1% | 26 | $578.60 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 3,586 | $549.10 |
| 93296 | <1% | 74 | $529.48 | |
| 94618 | <1% | 41 | $523.09 | |
| 87641 | <1% | 14 | $513.91 | |
| 84460 | <1% | 78 | $493.33 | |
| 83001 | <1% | 27 | $489.69 | |
| 82785 | <1% | 26 | $479.93 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 7,468 | $447.80 |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 73 | $433.52 |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 12 | $415.19 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,053 | $391.83 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 3,012 | $357.28 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 3,262 | $352.50 |
| J2704 | Injection, propofol, 10 mg | <1% | 1,433 | $347.85 |
| 86705 | <1% | 25 | $341.78 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 209 | $309.20 |
| 90686 | <1% | 49 | $291.44 | |
| 87205 | <1% | 70 | $271.79 | |
| G0008 | Administration of influenza virus vaccine | <1% | 64 | $271.20 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 3,440 | $260.22 |
| 82103 | <1% | 14 | $259.42 | |
| 71101 | <1% | 12 | $251.02 | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 339 | $237.30 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,670 | $208.74 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 29 | $205.00 |
| 86200 | <1% | 13 | $204.72 | |
| 86800 | <1% | 12 | $201.12 | |
| 86039 | <1% | 12 | $179.85 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,021 | $160.68 |
| 82077 | <1% | 19 | $152.90 | |
| 87046 | <1% | 68 | $150.75 | |
| 73140 | <1% | 13 | $150.63 | |
| 88304 | <1% | 27 | $147.19 | |
| 83721 | <1% | 16 | $136.97 | |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 281 | $128.99 |
| 80069 | <1% | 16 | $125.45 | |
| 80178 | <1% | 14 | $103.29 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 1,103 | $98.40 |
| 72170 | <1% | 13 | $85.43 | |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 12 | $49.90 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 103 | $44.79 |
| 84520 | <1% | 12 | $41.98 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 2,123 | $34.27 |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 132 | $24.14 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 157 | $19.03 |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 68 | $10.16 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 549 | $0.00 |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 392 | $0.00 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 49 | $0.00 |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | 0% | 266 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 46 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 45 | $0.00 |
| J1750 | Injection, iron dextran, 50 mg | 0% | 14 | $0.00 |
| J0134 | Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg | 0% | 26 | $0.00 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | 0% | 246 | $0.00 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 60 | $0.00 |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 0% | 20 | $0.00 |
| C9399 | Unclassified drugs or biologicals | 0% | 30 | $0.00 |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | 0% | 13 | $0.00 |
| 90656 | 0% | 56 | $0.00 | |
| J1597 | Injection, glycopyrrolate (glyrx-pf), 0.1 mg | 0% | 56 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 76 | $0.00 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 13 | $0.00 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 0% | 12 | $0.00 |
| J1815 | Injection, insulin, per 5 units | 0% | 41 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMULL, CINDY (SYSTEM DIRECTOR ENROLLMENT)
| Provider | Location | Paid |
|---|---|---|
| Geisinger Clinic | Danville, PA | $74.54M |
| Community Medical Center | Scranton, PA | $22.62M |
| Geisinger Clinic | Danville, PA | $14.93M |
| West Shore Advanced Life Support Services, INC. | Danville, PA | $4.41M |
| Geisinger Clinic | Pottsville, PA | $3.39M |
| Geisinger Clinic | Lewistown, PA | $2.93M |
| Geisinger Clinic | Scranton, PA | $2.63M |
| Geisinger Clinic | Wilkes Barre, PA | $2.35M |
| Geisinger Clinic | Danville, PA | $2.28M |
| Geisinger Jersey Shore Hospital | Jersey Shore, PA | $2.17M |
| Geisinger Clinic | Scranton, PA | $1.71M |
| Geisinger Clinic | Tunkhannock, PA | $1.11M |
| Geisinger Clinic | Orwigsburg, PA | $974K |
| Geisinger Clinic | Pittston, PA | $942K |
| Geisinger Clinic | Berwick, PA | $896K |
| Geisinger Clinic Selinsgrove | Selinsgrove, PA | $819K |
| Geisinger Clinic | Philipsburg, PA | $678K |
| Geisinger Clinic | Lewisburg, PA | $557K |
| Geisinger Clinic | Mountain Top, PA | $523K |
| Geisinger Clinic | Kulpmont, PA | $489K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.